← Back to headlines
Elicio Stock Falls After Pancreatic Cancer Drug Fails Phase 2 Trial
Elicio Therapeutics' stock experienced a significant drop following the release of disappointing phase 2 clinical trial data for its pancreatic cancer treatment.
15 Jun, 15:24 — 15 Jun, 15:24
Sources
Showing 1 of 1 sources
Related Stories
Irish Health Agency Fined €645,000 for Storing Records in Derelict Sites
51m ago
New Urine Test Detects Over 90 Percent of Bladder Cancer Cases
1h ago
Swimmer Hospitalized Following Suspected Shark Attack in Massachusetts
4h ago
Wellington Clinics Suspends Kidney Transplants Amid Organ Harvesting Probe
10h ago